-

MiNA Therapeutics Enters Research Collaboration with BioMarin Pharmaceutical to Advance RNAa Platform Research in Rare Genetic Diseases

- Collaboration includes licensing agreement options based on early-stage clinical outcomes

LONDON--(BUSINESS WIRE)--MiNA Therapeutics, the pioneer of small activating RNA (RNAa) therapeutics, today announced a multi-target research collaboration and option licensing agreement with BioMarin Pharmaceutical Inc. The collaboration will allow for the discovery, and potential development and commercialization of RNAa therapeutic candidates targeting a number of rare genetic diseases.

Under the agreement, BioMarin will employ MiNA Therapeutics’ proprietary RNAa algorithm and technology platform to identify and characterize RNAa molecules targeting a number of genetic diseases for which there are currently no or minimal therapeutic options. The agreement does not cover oncology, or other therapeutic areas outside of genetic disease. BioMarin may then elect to license the assets fully for worldwide development and commercialization.

"We are proud to announce this collaboration with BioMarin, a global leader in the development and commercialization of treatments for rare genetic diseases,’’ said Robert Habib, Chief Executive Officer at MiNA. “Our RNAa therapeutic platform has delivered unique and differentiated clinical benefits in other early clinical studies, demonstrating that MiNA’s platform may have significant benefits over other genetic medicine approaches.’’

As part of the deal, MiNA will receive an upfront payment and future royalties will be subject to BioMarin exercising options from the deal. Financial terms of the agreement were not disclosed.

“Activating RNA therapeutics have the potential to change the way we treat certain genetic diseases, particularly those characterized by the limited production of key proteins,” said Kevin Eggan, Ph.D., Senior Vice President and Chief Scientific Officer of BioMarin. “For more than two decades, BioMarin has advanced innovative medicines designed to transform the lives of people with genetic conditions. This collaboration with MiNA continues that legacy of innovation, creating a partnership around a novel scientific approach that we believe will allow us to target the root cause of several genetic disorders in a new way.”

MiNA’s RNAa platform has been clinically validated in more than 120 patients to date. The universally designed platform has the potential to address any gene given its endogenous mechanism of action that ultimately addresses the root cause of the defective gene and enables the body to self-correct. Furthermore, working at the gene level, RNAa medicines are able to restore a cell’s own biology. This holds potential to treat currently “undruggable” diseases.

About MiNA Therapeutics

MiNA Therapeutics is the leader in small activating RNA therapeutics. Harnessing innate mechanisms of gene activation, small activating RNA therapeutics are a revolutionary new class of medicines that can restore normal function to patients’ cells. We are advancing a proprietary pipeline of new medicines with an initial focus on cancer and genetic diseases, while collaborating with leading pharmaceutical companies to apply our technology platform across a broad range of therapeutic areas. Based on our unique know-how in RNA activation we are expanding the possibilities of RNA-based medicine for patients. For more information, visit www.minatx.com.

Contacts

Corporate Contact:
Robert Habib
info@minatx.com
+44 208 811 6700

Media Contact:
Mike Beyer
Sam Brown, Inc.
mikebeyer@sambrown.com
+1 312-961-2502

MiNA Therapeutics


Release Versions

Contacts

Corporate Contact:
Robert Habib
info@minatx.com
+44 208 811 6700

Media Contact:
Mike Beyer
Sam Brown, Inc.
mikebeyer@sambrown.com
+1 312-961-2502

More News From MiNA Therapeutics

MiNA Therapeutics Appoints Norbert Bischofberger, Ph.D., to its Board as Non-Executive Director and Bríd Ryan, Ph.D., MPH, as Chief Scientific Officer

LONDON--(BUSINESS WIRE)--MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, has appointed Norbert Bischofberger, Ph.D., as a Non-Executive Director to its Board of Directors and has promoted Bríd Ryan, Ph.D., MPH, to Chief Scientific Officer, who most recently served as Senior Vice President, Research. Dr. Bischofberger is a recognised leader in the biotechnology field, most recently serving as President and Chief Executive Officer of Kronos Bio. Prior to this,...

MiNA Therapeutics Presents New Pre-Clinical Data from Lead Sickle Cell Disease Program at the American Society of Hematology Annual Meeting

LONDON--(BUSINESS WIRE)--MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, today presented new pre-clinical data for its lead RNA activation program for the treatment of sickle cell disease, which demonstrated best-in-class activity and safety. The data shared at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego will also be highlighted at a poster walk session on December 9, 2024, at 12:30 pm PST. MTL-HBG is an RNAa medicine designed to...

MiNA Therapeutics Enters Research Collaboration with Nippon Shinyaku to Develop RNAa Therapeutics Targeting Rare Neurodegenerative Diseases

LONDON--(BUSINESS WIRE)--MiNA Therapeutics, the pioneer of small activating RNA (RNAa) therapeutics, today announced a research collaboration and licensing agreement option with Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters: Kyoto; President: Toru Nakai), an innovation-driven Japanese-based pharmaceutical company focused on disease areas of high unmet medical need. The collaboration will allow for the discovery, and potential development and commercialization of RNAa therapeutic cand...
Back to Newsroom